CN103966224A - 一种适配子及其筛选方法和应用 - Google Patents
一种适配子及其筛选方法和应用 Download PDFInfo
- Publication number
- CN103966224A CN103966224A CN201410198044.XA CN201410198044A CN103966224A CN 103966224 A CN103966224 A CN 103966224A CN 201410198044 A CN201410198044 A CN 201410198044A CN 103966224 A CN103966224 A CN 103966224A
- Authority
- CN
- China
- Prior art keywords
- albumen
- kiaa0157
- aptamer
- protein
- ssdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091023037 Aptamer Proteins 0.000 title claims description 29
- 238000012216 screening Methods 0.000 title claims description 17
- 238000000034 method Methods 0.000 title description 7
- 102100024635 BRISC complex subunit Abraxas 2 Human genes 0.000 claims abstract description 32
- 101000760684 Homo sapiens BRISC complex subunit Abraxas 2 Proteins 0.000 claims abstract description 32
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000001514 detection method Methods 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 24
- 102000053602 DNA Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000012148 binding buffer Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 8
- 238000007846 asymmetric PCR Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- -1 nitrite ions Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
适配子名称 | 亲和力 | 适配子名称 | 亲和力 |
K1 | 0.54 | K10 | 0.46 |
K4 | 0.50 | K13 | 0.57 |
K5 | 0.57 | K17 | 0.55 |
K8 | 0.55 | K20 | 0.53 |
K9 | 0.60 | K22 | 0.52 |
适配子名称 | Kd值(nM) | 适配子名称 | Kd值(nM) |
K1 | 54.0 | K10 | 0.46 |
K4 | 52.7 | K13 | 38.59 |
K5 | 42.8 | K17 | 40.26 |
K8 | 50.5 | K20 | 41.57 |
K9 | 37.26 | K22 | 45.41 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410198044.XA CN103966224B (zh) | 2014-05-12 | 2014-05-12 | 一种适配子及其筛选方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410198044.XA CN103966224B (zh) | 2014-05-12 | 2014-05-12 | 一种适配子及其筛选方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103966224A true CN103966224A (zh) | 2014-08-06 |
CN103966224B CN103966224B (zh) | 2016-07-13 |
Family
ID=51236230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410198044.XA Expired - Fee Related CN103966224B (zh) | 2014-05-12 | 2014-05-12 | 一种适配子及其筛选方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103966224B (zh) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104962560A (zh) * | 2015-06-16 | 2015-10-07 | 湖南大学 | 一种检测日本血吸虫卵的核酸适配体及其在制备检测制剂中的应用 |
CN105693849A (zh) * | 2014-07-13 | 2016-06-22 | 马海龙 | 一种特异性针对Neutrokine-α蛋白的核酸适配体NKXA5及其应用 |
CN105693848A (zh) * | 2014-07-13 | 2016-06-22 | 马海龙 | 一种特异性针对Neutrokine-α蛋白的核酸适配体NKXA7及其应用 |
CN105693847A (zh) * | 2014-07-13 | 2016-06-22 | 马海龙 | 一种特异性针对Neutrokine-α蛋白的核酸适配体NKXA9及其应用 |
CN106349361A (zh) * | 2016-11-09 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349362A (zh) * | 2016-11-09 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349360A (zh) * | 2016-11-09 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349363A (zh) * | 2016-11-10 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349358A (zh) * | 2016-11-07 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349359A (zh) * | 2016-11-07 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349366A (zh) * | 2016-11-14 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349365A (zh) * | 2016-11-14 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349364A (zh) * | 2016-11-10 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106397567A (zh) * | 2016-11-08 | 2017-02-15 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106397566A (zh) * | 2016-11-07 | 2017-02-15 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106432464A (zh) * | 2016-11-08 | 2017-02-22 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106432465A (zh) * | 2016-11-08 | 2017-02-22 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106432466A (zh) * | 2016-11-10 | 2017-02-22 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106478799A (zh) * | 2016-11-14 | 2017-03-08 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN109804081A (zh) * | 2018-11-08 | 2019-05-24 | 廖世奇 | 一种复合靶标-肿瘤血清核酸配基检测方法及试剂盒 |
CN113234728A (zh) * | 2021-06-09 | 2021-08-10 | 集美大学 | 一种温度性敏感位点核酸适配体及其筛选方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101148667A (zh) * | 2006-09-22 | 2008-03-26 | 国家纳米技术与工程研究院 | 一种亲和人白蛋白核酸适配子的制备与用途 |
CN101712958A (zh) * | 2008-10-08 | 2010-05-26 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种新的人肿瘤抑制基因kiaa0157及其应用 |
CN102766632A (zh) * | 2012-07-09 | 2012-11-07 | 徐霞 | 一种高尔基体膜蛋白gp73核酸适配子、其制备方法及其用途 |
-
2014
- 2014-05-12 CN CN201410198044.XA patent/CN103966224B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101148667A (zh) * | 2006-09-22 | 2008-03-26 | 国家纳米技术与工程研究院 | 一种亲和人白蛋白核酸适配子的制备与用途 |
CN101712958A (zh) * | 2008-10-08 | 2010-05-26 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种新的人肿瘤抑制基因kiaa0157及其应用 |
CN102766632A (zh) * | 2012-07-09 | 2012-11-07 | 徐霞 | 一种高尔基体膜蛋白gp73核酸适配子、其制备方法及其用途 |
Non-Patent Citations (1)
Title |
---|
登录号: "NP_115558", 《NCBI GENBANK》 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105693849A (zh) * | 2014-07-13 | 2016-06-22 | 马海龙 | 一种特异性针对Neutrokine-α蛋白的核酸适配体NKXA5及其应用 |
CN105693848A (zh) * | 2014-07-13 | 2016-06-22 | 马海龙 | 一种特异性针对Neutrokine-α蛋白的核酸适配体NKXA7及其应用 |
CN105693847A (zh) * | 2014-07-13 | 2016-06-22 | 马海龙 | 一种特异性针对Neutrokine-α蛋白的核酸适配体NKXA9及其应用 |
CN104962560A (zh) * | 2015-06-16 | 2015-10-07 | 湖南大学 | 一种检测日本血吸虫卵的核酸适配体及其在制备检测制剂中的应用 |
CN106397566A (zh) * | 2016-11-07 | 2017-02-15 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349358A (zh) * | 2016-11-07 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349359A (zh) * | 2016-11-07 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106397567A (zh) * | 2016-11-08 | 2017-02-15 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106432465A (zh) * | 2016-11-08 | 2017-02-22 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106432464A (zh) * | 2016-11-08 | 2017-02-22 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349362A (zh) * | 2016-11-09 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349360A (zh) * | 2016-11-09 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349361A (zh) * | 2016-11-09 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349364A (zh) * | 2016-11-10 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349363A (zh) * | 2016-11-10 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106432466A (zh) * | 2016-11-10 | 2017-02-22 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349365A (zh) * | 2016-11-14 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106349366A (zh) * | 2016-11-14 | 2017-01-25 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN106478799A (zh) * | 2016-11-14 | 2017-03-08 | 李露青 | 一种人肿瘤抑制蛋白变体及其应用 |
CN109804081A (zh) * | 2018-11-08 | 2019-05-24 | 廖世奇 | 一种复合靶标-肿瘤血清核酸配基检测方法及试剂盒 |
CN113234728A (zh) * | 2021-06-09 | 2021-08-10 | 集美大学 | 一种温度性敏感位点核酸适配体及其筛选方法 |
CN113234728B (zh) * | 2021-06-09 | 2023-09-19 | 集美大学 | 一种温度性敏感位点核酸适配体及其筛选方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103966224B (zh) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103966224A (zh) | 一种适配子及其筛选方法和应用 | |
CN104109194A (zh) | Sfrp1蛋白的适配子及其筛选方法和应用 | |
Sun et al. | Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma | |
Wang et al. | Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity | |
Chai et al. | SELEX (Systematic Evolution of Ligands by EXponential Enrichment), as a powerful tool for deciphering the protein–DNA interaction space | |
Cao et al. | A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer | |
Wildner et al. | Aptamers as quality control tool for production, storage and biosimilarity of the anti-CD20 biopharmaceutical rituximab | |
Miao et al. | Terminal deoxynucleotidyl transferase-induced DNAzyme nanowire sensor for colorimetric detection of lipopolysaccharides | |
Catuogno et al. | Developing aptamers by cell-based SELEX | |
CN104031137B (zh) | 鳐血管生成抑制因子1的适配子及其筛选方法和应用 | |
CN102703455B (zh) | 一种人心肌肌钙蛋白i适配子及筛选方法和应用 | |
CN102010865A (zh) | 一种特异识别单核细胞增生李斯特菌的核酸适配子及其筛选方法与应用 | |
RU2019103083A (ru) | МУТАЦИИ ErbB3 ПРИ РАКЕ | |
Chen et al. | Toehold-mediated ligation-free rolling circle amplification enables sensitive and rapid imaging of messenger RNAs in situ in cells | |
KR101535892B1 (ko) | 살모넬라 티피뮤리움 균주의 ompC단백질에 대해 결합하는 RNA 앱타머 | |
CN108387561B (zh) | 一种基于碱基淬灭荧光原理实现低成本高通量核酸适配体最优序列的优化方法 | |
CN102226185A (zh) | 靶向肝细胞的rna适配子及其核苷酸序列 | |
CN106011142B (zh) | 一种特异识别psa蛋白的寡核苷酸配基p7-26的序列和应用 | |
CN105669852B (zh) | 鳐血管生成抑制因子1的适配子k10及其筛选方法和应用 | |
CN105646695B (zh) | 鳐血管生成抑制因子1的适配子k16及其筛选方法和应用 | |
CN105669851B (zh) | 鳐血管生成抑制因子1的适配子k6及其筛选方法和应用 | |
CN105713081B (zh) | 鳐血管生成抑制因子1的适配子k17及其筛选方法和应用 | |
CN104988155B (zh) | 与人鼻咽癌lmp2a结合的适配子及其构成的生物芯片 | |
Daldrop et al. | The functional exchangeability of pk-and k-turns in RNA structure | |
Shagin et al. | Application of nonsense-mediated primer exclusion (NOPE) for preparation of unique molecular barcoded libraries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160506 Address after: 315137 Zhejiang city of Ningbo province Yinzhou District Yunlong Town Li Yun Road No. 10 Applicant after: Zhu Yupan Address before: Yinzhou District Heng Jie Heng Jie Zhen Road 315181 No. 50 Zhejiang city of Ningbo Province Applicant before: Hua Guoguang |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Dong Ruihua Inventor before: Hua Guoguang |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170228 Address after: Chunhui road 400084 Dadukou District of Chongqing cypress Road No. 101 Building 1 Street 2-1, 2-2, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9 Patentee after: Chongqing Diweina Biological Technology Co. Ltd. Address before: 315137 Zhejiang city of Ningbo province Yinzhou District Yunlong Town Li Yun Road No. 10 Patentee before: Zhu Yupan |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160713 Termination date: 20200512 |
|
CF01 | Termination of patent right due to non-payment of annual fee |